This is what cardiologist Hooman Noorchashm warned about:
Retired surgeon Dr. Hooman Noorchashm warned "Tucker Carlson Tonight" Monday that while the coronavirus vaccine should be viewed as a medical miracle, applying a "one-size-fits-all" approach, as many experts are, could cause more harm to some patients.
www.foxnews.com
Dr. Hooman Noorchashm says FDA, Pfizer and Moderna must consider the danger COVID vaccines pose to the recently convalescent or asymptomatic carriers of SARS-CoV-2 — especially the elderly, frail or anyone with significant cardiovascular risk factors.
www.lifesitenews.com
18 Connecticut teens hospitalized for heart problems after COVID vaccines, White House says young people should still get the shots
The mother of 17-year-old Gregory Hatton, diagnosed with pericarditis within days of his second dose of the vaccine, said her son 'basically has a heart condition now and it’s terrifying.'
www.lifesitenews.com
From his letter to FDA LAST JANUARY:
“...As you know, the SARS-CoV-2 virus has tropism for the vascular endothelium, among other tissues and organs. This fact was captured in a Lancet paper published in April 2020:
Cardiovascular complications are rapidly emerging as a key threat in coronavirus disease 2019 (COVID-19) in addition to respiratory disease. The mechanisms underlying the disproportionate effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with...
www.thelancet.com
As you also know it appears that the ACE-2 receptor on endothelium is the portal for viral entry into endothelial cells — and it seems that endothelial injury from the virus or from the inflammatory reaction it incites, is the reason why many COVID-19 patients experience thromboembolic complications.
So it is a matter of certainty that viral antigens are present in the endothelial lining of blood vessels in all persons with active or recent SARS-CoV-2 infection — irrespective of whether they are symptomatic or convalescent.
I am writing to warn that it is an almost certain immunological prognotication that if viral antigens are present in the tissues of subjects who undergo vaccination, the antigen specific immune response triggered by the vaccine will target those tissues and cause tissue inflammation and damage.
Most pertinently, when viral antigens are present in the vascular endothelium, and especially in elderly and frail with cardiovascular disease, the antigen specific immune response incited by the vaccine is almost certain to do damage to the vascular endothelium. Such vaccine directed endothelial inflammation is certain to cause blood clot formation with the potential for major thromboembolic complications, at least in a subset of such patients. If a majority of younger more robust patients might tolerate such vascular injury from a vaccine immune response, many elderly and frail patients with cardiovascular disease will not.
Therefore, it is my respectful request that FDA, in collaboration with Pfizer and Moderna, immediately and at the very minimum, institute clear recommendations to clinicians that they delay immunization in any recently convalescent patients, as well as, any known symptomatic or asymptomatic carriers — and to actively screen as many patients with high cardiovascular risk as is reasonably possible, in order to detect the presence of SARS-CoV-2, prior to vaccinating them.“